Keyword: Bristol-Myers Squibb
Emotion is a strong decision driver, especially in healthcare—so important, in fact, that Havas Health & You has launched a new agency to focus on it.
Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.
The math is simple, but managing a company isn’t. That’s the message we gleaned in analyzing productivity at major pharmas and biotech companies.
The same day that Bristol-Myers Squibb reported a closely watched clinical win, the drugmaker announced Street-beating results.
Bristol-Myers finally got its win in first-line lung cancer, with a one-two punch of its PD-1 drug Opdivo and CTLA4 drug Yervoy.
Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.
Outcome Health co-founders Rishi Shah and Shradha Agarwal will step aside from day-to-day management to appease angry investors.
Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.
Merck & Co.'s Keytruda posted some new melanoma data that could help it play catch-up with Bristol-Myers' Opdivo.